Representative Matsui News Today

Jennifer Mathieu, senior vice president of professional and government affairs at AMCP, provides an update on the Access to Prescription Digital Therapeutics Act 2023 moving through Congress.

Sen. Mazie Hirono (D-HI) and Rep. Doris Matsui (D-CA) reintroduced the Patsy T. Mink and Louise M. Slaughter Gender Equity in Education Act of 2023 (S. 2145/HR 4342) to celebrate Title...

U.S. Secretary of Commerce Gina M. Raimondo released the following statement following President Biden’s signing of the CHIPS and Science Act of 2022.

The next-generation of wireless technologies – known as 5G – is here. Not only is it expected to offer network speeds that are up to 100 times faster than 4G LTE and reduce latency to nearly zero...

Leading policymakers – federal regulators and legislators – are making it a top priority to ensure that the wireless industry has the tools it needs to maintain U.S. leadership in commercial 5G deployments.

Photo: Jeff Lagasse/Healthcare Finance News Six drugmakers who have violated the 340B statute should immediately begin offering drugs at discounted prices to hospitals participating in the federal drug-pricing program, according to a letter sent to the drugmakers this week from the Health Resources and Services  Administration. The HRSA maintained that the drug manufacturers in question – AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, Sanofi and United Therapeutics – placed restrictions o...